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Abstract
Background: Multi-drug resistant tuberculosis (MDR-TB) is a major public health problem especially in developing
countries. World Health Organization (WHO) recommends use of Xpert MTB/RIF assay to simultaneously detecting
Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance. The primary objective of this study was to
determine the frequency of MDR-TB in patients suspected to have drug resistance in Khyber Pakhtunkhwa. The
frequency of probes for various rpoB gene mutations using Xpert MTB/RIF assay within 81 bp RRDR (Rifampicin
Resistance Determining Region) was the secondary objective.
Methods: A total of 2391 specimens, received at Programmatic Management of Drug Resistant TB (PMDT) Unit,
Lady Reading Hospital (LRH) Peshawar, Pakistan, between October 2011 and December 2014, were analyzed by
Xpert MTB/RIF test. MTB positive with rifampicin resistance were further analyzed to first line anti-mycobacterial
drug susceptibility testing (DST) using middle brook 7H10 medium. The data was analyzed using statistical software;
SPSS version 18.
Results: Out of 2391 specimens, 1408 (59 %) were found positive for MTB and among them, 408 (29 %) showed
rifampicin-resistance with four different rpoB gene mutations within 81 bp RRDR. The frequency of various probes
among RIF-resistant isolates was observed as: probe E, in 314 out of 408 isolates; B, 44 out of 408; A, 5 out of 408;
D, 34 out of 408; and probe C was observed among 6 out of 408 RIF-resistant isolates. The probe A&B and E&D
mutation combination was found in only 1 isolate in each case, while B&D mutation combination was detected
among 3 out of 408 RIF-resistant isolates.
Conclusions: Hence, it is concluded from our study on a selected population, 29 % of patients had MDR-TB.
Probe E related mutations (also known as codon 531and 533) were the most common rpoB genetic mutation
[314 (77 %)], acknowledged by Xpert MTB/RIF assay. Least mutation was detected within the sequence 511 (1.2 %).
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Background
Multi-drug resistant tuberculosis (MDR-TB), is defined
as a form of TB infection caused by Mycobaterium tu-
berculosis that is resistant to treatment with at least two
of the most powerful first-line anti-TB drugs, isoniazid
and rifampicin [1]. Rifampicin (RIF) resistance is of
specific epidemiological importance and a valuable sur-
rogate marker for MDR-TB strains as more than 90 %
RIF resistant strains are also resistant to isoniazid [2, 3].
Introduction of Xpert MTB/RIF assay (Cepheid, USA)
has revolutionized the diagnosis of TB by simultaneously
detecting MTB and rifampicin resistance [4, 5]. Rifampicin
is one of the key first-line anti-tuberculosis drug, which
inhibits DNA-directed ribonucleic acid synthesis of MTB
proteins by binding to the β-subunit of bacterial DNA
dependent RNA polymerase enzyme (rpoB) protein. In
general, rpoB mutations is found in 95–97 % of RIF-
resistant MTB strains worldwide and these mutations
are typically located in a region at the 507–533 amino
acid residuals (81 bp) within the rpoB genetic factor,
that is usually referred to as Rifampicin Resistant
Determinant Region (RRDR) [6].
Pakistan ranks 5th among 22 high TB burden countries
and 4th among MDR-TB countries. WHO report showed
that the prevalence of MDR-TB was 4 % and 35 % among
all new and previously treated TB cases, respectively [1].
The biological features of bacteria as well as drug resist-
ance typically vary in different geographical areas [7–9].
Data on prevalence of rpoB gene mutations in Pakistan is
limited, so this study is aimed to provide reference line
data on these mutations using Xpert MTB/RIF assay. The
detection of rpoB gene mutations is most important for
accurate diagnosis of RIF resistance in MTB strains [10].
The current study was aimed to investigate the frequency
of RIF-resistant MTB strains in specimens collected from
TB presumptive patients in Khyber Pakhtoonkhwa,
Pakistan and also mutations at RRDR within the rpoB
gene of RIF-resistant MTB using Xpert MTB/RIF assay.
Methods
We studied 2391 patients in this study. Each patient was
required to provide one sputum specimen.
Clinical specimens
Total numbers of 2391 specimens from any drug resist-
ant TB presumptive patients were received at PMDT,
LRH between October 2011 and December 2014. All
these specimens were investigated for detection of
MTB as well as resistance to the first-line anti-TB drug,
Rifampicin using Xpert MTB/RIF. The referrals of these
specimens were according to the guidelines of NTP for
Xpert MTB/RIF.
Criteria for testing on Xpert MTB/RIF
The following criteria was considered for testing speci-
mens on Xpert MTB/RIF: 1. All smear positive new
cases that remain positive by the end of 2nd month of
treatment; 2. Failure of Cat-I and Cat-II; 3. Re-treated
pulmonary cases both smear positive and smear nega-
tive;4. Contact with MDR-TB patients; and 5. TB/HIV
co-infection cases were considered for testing through
Xpert MTB/RIF.
Important details and specimen characteristics (volume
and consistence) were recorded in laboratory data assort-
ment forms and later on transferred to access restricted
computer-based database. These specimens included
sputa, cerebral spinal fluid (CSF), pleural fluid, pus, ascetic
fluid, pericardial fluid and bronchial wash (Table 1). TB
diagnostics requests ranged from microscopy, culture and
Xpert test. In addition to routine analysis, we also per-
formed DST on all MTB positive and rifampicin resistant
detected (RRD) cases that were identified by Xpert MTB/
RIF test as shown in Fig 1.
Drug susceptibility testing
Drug susceptibility testing was performed using the
standard agar proportion method on enriched Middle
brook 7H10 medium (BBL, Bechton Dickinson and
Company, New Jersey) at the following drug concentra-
tion: Isoniazid 0.2 and 1 μg/ml, rifampicin 1 and 5 μg/
ml, ethambutol 5 and 10 μg/ml and streptomycin 2 and
10 μg/ml [11, 12]. Mycobacterium tuberculosis H37Rv
(sensitive to all anti-tuberculosis drugs) was used as ref-
erence control strain. The drugs were used at critical
concentrations.
MTB/RIF assay
Non-sterile clinical specimens were processed by the
standard N-acetyl-L-cysteine–NaOH technique. [13]
Smears were prepared by the auramine-rhodamine acid-
fast staining technique. The MTB/RIF assay was done as
described previously [4, 14]. N-acetyl-L-cysteine–NaOH
was added to the clinical specimens at a 3:1 ratio, for de-
contamination in a closed specimen. The container was
manually agitated 15-min period at room temperature.
Table 1 Breakdown of samples in extra pulmonary Tuberculosis
Sample name Frequency (%)
Sputum 2272 (95)
Bronchial Wash 54 (2.2)
Ascetic fluid 23 (1)
CSF 8 (0.3)
PUS 23 (1)
Pericardial fluid 11 (0.5)
Total 2391
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2 ml of inactivated specimen was transferred to the
Xpert test cartridge and tested according to manufactur-
er's guide [4, 14].
Statistical analysis
The data was analyzed by using Statistical Package for
Social Sciences (SPSS 18).
Results
Xpert® MTB/RIF assay
Out of RRD cases, 42 (3 %) were new and 366 (26 %)
previously treated cases. Females were 243 (59.6 %) and
males 165 (40.4 %). Maximum number of RRD patients
was found in the age group 15–24 years (38.5 %) as
shown in Table 2.
Among 2391 specimens tested by Xpert MTB/RIF,
MTB was detected in 1408 (58.9 %) specimens. Out of
total MTB cases, 408 (29 %) were detected to have RIF-
resistance. The resistance was given by four totally
different rpoB gene mutations within the 81 bp-RRDR of
MTB. These were detected by A, B, C D, E, A&B, B&D
and E&D probes. The probe frequency that reflects RIF-
resistance was observed as follows: probe A frequency
was 1.2 %; B, 10.8 %; C, 1.5 %; D, 8.3 %; and probe E
frequency was highest (77 %) among all. Mutation
combination of probe A&B and E&D was 0.25 %, while
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Fig. 1 Flow chart of specimens’ analysis (submitted separately via online)
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408 RRD cases, checked by Xpert MTB/RIF were
further subjected to DST. Out of 408 cases, 19 (4.6 %)
were failed to show RIF-resistance, 5 (1.2 %) mono re-
sistant and 14 (3.4 %) showed poly resistance to first-line
anti-TB drugs other than rifampicin, while 386 (94.6 %)
cases were found to be MDR on DST (Table 3). 252
(61.6 %) cases were resistant to all first-line anti-TB
drugs while 386 (94.6 %) cases of rifampicin resistant
were also found resistant to isoniazid.
Discussion
The genetic basis of anti-tuberculosis drug resistant
MTB isolates has been widely studied worldwide and
commonly believed to be caused by point mutations in
some important genes like rpoB, katG, rpsL, embB etc.
[6]. Meanwhile globally MDR-TB is big threat to human
especially in developing countries, therefore in the
present study we use Xpert MTB/RIF to check drug re-
sistant isolates of MTB for mutation in the rpoB gene of
rifampicin as more than 90 % strains are also resistant to
isoniazid [2, 3]. Khyber Pakhtoonkhwa is one of the four
provinces of Pakistan, that share a common border with
Afghanistan, and over 30 Million population. To the best
of our knowledge, this is the first report ever in this re-
gion where Xpert MTB/RIF method has been used for
studying over all prevalence of MTB. This study is of
great significance because it would provide baseline data
in case if the scope is extended to other provinces in
Pakistan.
Xpert MTB/RIF test is increasingly used in developing
high burden countries to diagnose drug resistant MTB,
while conventional test such as culture based DST is
considered to be a “gold standard” for MDR-TB. In the
present study, 389 (95.4 %) MTB isolates, found RIF
resistant by Xpert MTB/RIF test, were confirmed to be
resistant to RIF by DST. However the remaining 19
(4.6 %) isolates, initially diagnosed as resistant to RIF by
Xpert MTB/RIF, were tested susceptible to RIF by DST.
The previous reports indicates that lack of concordance
in the results are not due to performance of molecular
method [5, 15–18], but this discrepancy may be due to
well-known fact that not every genotypic modification of
Table 2 Detection of mutation in rpoB gene of rifampicin in rifampicin resistance detected (RRD) cases with different demographic
representation
Demography Probe types Total (%)
A B C D E A&B B&D E&D
Gender
Female 3 25 4 22 187 1 0 1 243 (59.6)
Male 2 19 2 12 127 0 3 0 165 (40.4)
History
New patients 1 1 1 4 35 0 0 0 42 (10.3)
Previously treated patients 4 43 5 30 279 1 3 1 366 (89.7)
Age categories (years)
<14 0 2 0 3 24 0 0 0 29 (7.1)
15- 24 0 14 3 12 125 1 2 0 157 (38.5)
25- 34 3 11 1 7 82 0 0 0 104 (25.5)
35- 44 2 9 0 2 36 0 0 0 49 (12)
45- 54 0 3 1 1 25 0 0 1 31 (7.6)
55- 64 0 3 1 7 19 0 0 0 30 (7.3)
64< 0 2 0 2 3 0 1 0 8 (2)
Table 3 Pattern of anti-TB drugs susceptibility testing against
RRD cases (n = 408) by Xpert MTB/RIF
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Ullah et al. BMC Infectious Diseases  (2016) 16:413 Page 4 of 6
rpoB gene affects phenotypic resistance to RIF corres-
pondingly. It has been observed in the previous studies
that the value of the RIF MIC strongly correlates with
the mutation in rpoB RRDR. [19, 20] Feuerriegel et al.
stated that in Sierra Leone, the isolates from re-
treatment cases were re-tested by DNA sequencing, 5
out of 21 (24 %) cases were found RIF susceptible by
DST. [21] In our view, the conventional test i.e. DST,
fails to detect mutation in 19 (4.6 %) isolates. Present
data indicates that these dissimilarities in mutation may
be due to poor clinical scenario that is utmost common
and undisputed, while few reports had previously sug-
gested that such isolates have clinical relevance [22, 23].
The most common RRDR rpoB gene mutations within
the 81 bp were detected in codons 531 (77 %), 513
(10.8 %), 526 (8.3 %), 511 (1.2 %), and 522 (1.5 %) se-
quences as selected by probes E, B, D, A, and C, respect-
ively, using Xpert MTB/ RIF assay. A study by Yue et al.
found these frequencies 531 (41 %), 526 (40 %), and 513
(4 %) in China [24]. Mboowa et al. also reported that
58 % mutations were in probe E in Kampala, Uganda
[25]. Khan et al. also described mutations in codons 531
(52 %), 516 (15 %) and 526 (7.0 %) in Punjab, Pakistan
[26]. These studies conclude that sequence 531 is the
most prevalent codon related to RIF-resistance. Accord-
ing to the previous studies, the sensitivity and specificity
of the MTB/RIF for detection of rifampicin resistance
was 94.4-100 % and 98.3-100 % [5, 27].
In current study, we have reported 29 % MDR-TB in
presumptive drug resistant TB patients in Khyber Pakh-
toonkhwa, which is similar to Liu et al. finding as 30.4 %
isolates were resistant to at least one first-line anti-TB
drug [28]. Luiz et al. reported 44.3 % isolates resistant to
at least one first-line anti-TB drug in Brazil which is
more than our findings [29]. Ullah et al. [30] and Javaid
et al. [11] reported 11.5 and 11.3 % resistance to at least
one anti-TB drug in different parts of Punjab, Pakistan.
In order to fight the risk MDR TB, a recent Drug Resist-
ant Survey, Study was conducted in Pakistan showed
that estimated percentage of MDR TB in new notified
TB cases is 4.3 % and in Re-treatment cases is 19.4 %
[1]. This difference may be due to geographical location,
sample size, and methodology for selection of presump-
tive patients for MDR-TB.
WHO expanded its MDR-TB detection program in 2012
within the high TB burden countries and use of Xpert
MTB/RIF Assay was approved for efficient detection of re-
sistance against anti-TB drugs [1]. Thus the assay could be
a useful tool in World’s fight against TB/MDR-TB espe-
cially in highTB burden countries such as Pakistan.
Conclusions
In this report, the Xpert MTB/RIF assay detected the RIF-
resistance associated mutations in RRDR 81 bp region.
Hence, it is concluded from our study on a selected
population, 29 % of patients had MDR-TB. Probe E
related mutations (also known as codon 531and 533)
were the most common rpoB genetic mutation [314
(77 %)], acknowledged by Xpert MTB/RIF assay. Least
mutation was detected within the sequence 511 (1.2 %).
Further studies ought to be done involving MDR-TB
strains isolated from Pakistani population in order and
data concerning these mutations would be helpful in
development of novel therapies against TB disease.
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